Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysis of bevacizumab plus erlotinib; concurrent osimertinib plus gefitinib for first-line treatment; and first-line treatment with a tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy (Abstracts 9506, 9507, 9508).
Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and local...
Eric Zhou, PhD, of Dana-Farber Cancer Institute, discusses an existing online program called SHUTi (Sleep Healthy Using the Internet), that he and his team adapted to the needs of ...
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete t...
Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab i...
Jeremy L. Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses data from the COVID-19 and Cancer Consortium cohort study, which included patients with active or prior he...